17-Hydroxyprogesterone caproate – Suspension of marketing authorisation
17/07/2024
Medicines for human use
Direct healthcare professional communication (DHPC)
Important Safety Information regarding 17-hydroxyprogesterone caproate: European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) recommends suspension of the marketing authorisation medicinal products containing 17-hydroxyprogesterone caproate